LAURA GARZA: Open Payments
NPI 1811351133 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,546 in 85 payments from 19 companies in 2025. Trend: 2023 $2,072 · 2024 $3,047 · 2025 $2,546
Food & beverage: $2,285Travel & lodging: $261
| Company | Payments | Amount |
|---|---|---|
| Boston Scientific Corporation | 7 | $532 |
| Novartis Pharmaceuticals Corporation | 30 | $375 |
| AstraZeneca Pharmaceuticals LP | 6 | $308 |
| Actelion Pharmaceuticals US, Inc. | 9 | $264 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $156 |
| E.R. Squibb & Sons, L.L.C. | 8 | $155 |
| ABIOMED | 1 | $150 |
| Novo Nordisk Inc | 2 | $144 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $141 |
| Amgen Inc. | 4 | $87 |
Products named: WATCHMAN Access System, LEQVIO, FARXIGA, JARDIANCE, OPSYNVI, Kerendia, CAMZYOS, Ozempic.
Industry payments across TX — which companies pay providers there.
